AR090425A1 - Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas - Google Patents

Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas

Info

Publication number
AR090425A1
AR090425A1 ARP130100566A ARP130100566A AR090425A1 AR 090425 A1 AR090425 A1 AR 090425A1 AR P130100566 A ARP130100566 A AR P130100566A AR P130100566 A ARP130100566 A AR P130100566A AR 090425 A1 AR090425 A1 AR 090425A1
Authority
AR
Argentina
Prior art keywords
immunoglobulins
suspension
plasma
cohn
cluster
Prior art date
Application number
ARP130100566A
Other languages
English (en)
Spanish (es)
Inventor
Peter Schwarz Hans
Bruckschwaiger Leopold
Gundinger Thomas
Nrnberger Julia
Teschner Wolfgang
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47833446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR090425(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR090425A1 publication Critical patent/AR090425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP130100566A 2012-02-23 2013-02-25 Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas AR090425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261602488P 2012-02-23 2012-02-23

Publications (1)

Publication Number Publication Date
AR090425A1 true AR090425A1 (es) 2014-11-12

Family

ID=47833446

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100566A AR090425A1 (es) 2012-02-23 2013-02-25 Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas

Country Status (25)

Country Link
US (1) US9782477B2 (enExample)
EP (2) EP4119574A1 (enExample)
JP (1) JP6291423B2 (enExample)
KR (1) KR101930582B1 (enExample)
CN (1) CN104245730B (enExample)
AR (1) AR090425A1 (enExample)
AU (1) AU2013203112B2 (enExample)
BR (1) BR112014020602B1 (enExample)
CA (1) CA2864715A1 (enExample)
CL (1) CL2014002225A1 (enExample)
CO (1) CO7081143A2 (enExample)
DK (1) DK2817334T3 (enExample)
EA (1) EA032478B1 (enExample)
ES (1) ES2928954T3 (enExample)
HU (1) HUE060195T2 (enExample)
IL (1) IL234103B (enExample)
MX (2) MX365236B (enExample)
MY (1) MY167235A (enExample)
NZ (1) NZ628529A (enExample)
PL (1) PL2817334T3 (enExample)
PT (1) PT2817334T (enExample)
SG (1) SG11201405149UA (enExample)
SI (1) SI2817334T1 (enExample)
TW (1) TWI629283B (enExample)
WO (1) WO2013126904A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN104004090A (zh) * 2014-06-12 2014-08-27 新疆德源生物工程有限公司 一种人免疫球蛋白的制备方法
CN104004091B (zh) * 2014-06-12 2016-08-17 新疆德源生物工程有限公司 一种人免疫球蛋白的制备工艺
GB201413227D0 (en) * 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
WO2017025965A1 (en) * 2015-08-13 2017-02-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2019219890A1 (en) * 2018-05-17 2019-11-21 Csl Behring Ag Method and system of protein extraction
IL293121A (en) * 2019-11-20 2022-07-01 Csl Behring Ag Method for extracting a protein from a precipitate and method for precipitating impurities
EP4118108A4 (en) * 2020-04-10 2024-05-15 Plasma Technologies, LLC COMPOSITIONS AND METHODS FOR HIGHLY EFFICIENT SIMPLIFIED PROTEIN ISOLATION
US20220380439A1 (en) * 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
CN112250757A (zh) * 2020-11-13 2021-01-22 广东深蓝生物科技有限公司 一种猪血浆中蛋白质的提取纯化方法
EP4271706A4 (en) * 2020-12-28 2025-01-15 Plasma Technologies LLC SYSTEMS AND METHODS FOR THE ISOLATION OF IMMUNGLOBULIN G ON A PROCESS SCALE
CN118580342B (zh) * 2024-05-20 2025-02-07 广东丹霞生物制药有限公司 一种静脉注射用人免疫球蛋白制剂的制备工艺

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US3998946A (en) 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) * 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
CA2232420A1 (en) 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
PT911037E (pt) 1997-10-23 2002-12-31 Mitsubishi Pharma Corp Preparacao de imunoglobulina armazenavel a temperatura ambiente para injeccao intravenosa
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
WO2003004982A1 (en) * 2001-07-05 2003-01-16 Hamamatsu Photonics K.K. Spectroscopic device
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
WO2005027821A2 (en) 2003-09-22 2005-03-31 Kamada Ltd. Large scale preparation of alpha-1 proteinase inhibitor and use thereof
EP1709077A1 (en) 2004-01-30 2006-10-11 Suomen Punainen Risti Veripalvelu Process for the manufacture of virus safe immunoglobulin
PL1718675T3 (pl) 2004-02-27 2013-09-30 Octapharma Ag Sposób uzyskiwania oczyszczonego preparatu przeciwciał pozbawionego wirusów
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
WO2008113589A1 (en) 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
BRPI1012082B1 (pt) * 2009-05-27 2022-08-16 Takeda Pharmaceutical Company Limited Método para preparar uma composição de igg concentrada a partir de plasma
AT514675B1 (de) * 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma

Also Published As

Publication number Publication date
KR101930582B1 (ko) 2018-12-18
PT2817334T (pt) 2022-10-17
CA2864715A1 (en) 2013-08-29
AU2013203112B2 (en) 2016-03-10
AU2013203112A1 (en) 2013-09-12
MY167235A (en) 2018-08-14
ES2928954T3 (es) 2022-11-23
US20130224183A1 (en) 2013-08-29
MX365236B (es) 2019-05-28
CN104245730A (zh) 2014-12-24
US9782477B2 (en) 2017-10-10
JP6291423B2 (ja) 2018-03-14
IL234103A0 (en) 2014-09-30
MX2019005999A (es) 2019-08-21
NZ628529A (en) 2016-09-30
HK1205520A1 (en) 2015-12-18
EP2817334A1 (en) 2014-12-31
EA032478B1 (ru) 2019-06-28
DK2817334T3 (da) 2022-10-03
KR20140135996A (ko) 2014-11-27
CL2014002225A1 (es) 2015-01-16
TWI629283B (zh) 2018-07-11
HUE060195T2 (hu) 2023-02-28
IL234103B (en) 2019-11-28
EP4119574A1 (en) 2023-01-18
EP2817334B1 (en) 2022-09-21
WO2013126904A1 (en) 2013-08-29
MX2014010076A (es) 2014-09-22
EA201491564A1 (ru) 2015-04-30
SG11201405149UA (en) 2014-09-26
BR112014020602A2 (pt) 2018-09-11
CN104245730B (zh) 2017-09-01
PL2817334T3 (pl) 2022-11-21
JP2015509506A (ja) 2015-03-30
TW201348248A (zh) 2013-12-01
BR112014020602B1 (pt) 2022-12-20
CO7081143A2 (es) 2014-10-10
SI2817334T1 (sl) 2022-11-30

Similar Documents

Publication Publication Date Title
AR090425A1 (es) Precipitacion de las fracciones i-iv-1 para obtener inmunoglobulinas plasmaticas
AR133787A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
MX2018009989A (es) Composiciones funcionales derivadas de frijol mungo.
CO5601037A2 (es) Anticuerpos anti-a beta y sus usos
SG10201909806SA (en) Production of t cell retargeting hetero-dimeric immunoglobulins
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
MX2019002252A (es) Metodo para producir una proteina de fusion de anticuerpo.
BR112012017124C1 (pt) Método para produzir e para purificar um multímero polipeptídico
BR112015031094A2 (pt) células progenitoras renais
CO6680653A2 (es) Fabricación del inhibidor inter-alfa(iaip) a partir de plasma
CL2021002168A1 (es) Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407).
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
CL2015000572A1 (es) Etanercept correctamente plegado de alta pureza y excelente rendimiento.
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
AR102324A1 (es) Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
BR112018008080A2 (pt) método para a fabricação de extratos especiais de symphytum
BR112017001966A2 (pt) ?método para produzir variantes com um fc com sialilação melhorada?
BR112016018826A8 (pt) anticorpo purificado, ou fragmento de ligação de antígeno, método para a identificação de uma população de células de esperma de mamífero portadoras de cromossomo x, e método in vitro para distorcer uma proporção entre os sexos
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
MX380226B (es) Proceso para preparar apolipoproteina a-i (apo a-i).
AR111465A1 (es) Método para la purificación de anticuerpos análogos por el uso de cromatografía de intercambio de cationes
BR112015014270A2 (pt) co-diferenciação de monócitos a partir de doadores alogênicos

Legal Events

Date Code Title Description
FC Refusal